Skip to main content
SpringerLink
Log in

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

In this review the clinical pharmacology of HIV protease inhibitors, a new class of antiretroviral drugs, is discussed. After considering HIV protease function and structure, the development of inhibitors of HIV protease is presented. Three protease inhibitors are reviewed in more detail: saquinavir, indinavir, and ritonavir. Clinical trial results with these agents are evaluated. Furthermore, adverse effects, resistance, dosage and administration, clinical pharmacokinetics, pharmacokinetic-pharmacodynamic relationships, and drug interactions are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Centers for Disease Control. Pneumocystis pneumonia-Los Angeles. MMWR 1981; 30:2.

    Google Scholar 

  2. Centers for Disease Control. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York city and California. MMWR 1981; 30:305–8.

    Google Scholar 

  3. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of 3'-amino-3'-deoxythymi dine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-con-trolled trial. N Engl J Med 1987; 317:185–91.

    Google Scholar 

  4. Delta Coordinating Committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348:283–91.

    Google Scholar 

  5. Hammer S, Katzenstein D, Hughes M, Gundacker H, Hirsch M, Merigan T. Nucleoside monotherapy (MT) vs. combination therapy (CT) in HIV infected adults: a randomized, doubleblind, placebo-controlled trial in persons with CD4 cell counts 200-500/mm3. V European Conference on Clinical Aspects and Treatment of HIV Infection, fifth plenary session, Copenhagen, September 1995.

  6. Van Cleef G, Polk RE, Fisher EJ. Drug interaction potential when HIV+ patients receive protease inhibitors. 36 th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, A28.

  7. Robins T, Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr 1993; 6:162–70.

    Google Scholar 

  8. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686–90.

    Google Scholar 

  9. Winslow DL, Otto MJ. HIV protease inhibitors. AIDS 1995; 9 Suppl A: S183–S192.

    Google Scholar 

  10. Kay J, Dunn BM. Viral proteinases: weakness in strength. Biochim Biophys Acta 1990; 1048: 1–18.

    Google Scholar 

  11. Copeland TD, Oroszlan S. Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease. Gene Anal Tech 1988; 5: 109–15.

    Google Scholar 

  12. Tomasselli AG, Hui JO, Sawyer TK, Staples DJ, Bannow C, Reardon IM, et al. Specificity and inhibition of proteases from human immunodeficiency virus 1 and 2. J Biol Chem 1990; 265: 14675–83.

    Google Scholar 

  13. Darke PL, Huff JR. HIV protease as an inhibitor target for the treatment of AIDS. Adv Pharmacol 1994; 25: 399–454.

    Google Scholar 

  14. Miller M, Jaskólski M, Rao JKM, Leis J, Wlodawer A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature (Lond) 1989; 337: 576–9.

    Google Scholar 

  15. Wlodawer A, Miller M, Jaskólski M. Conserved folding in ret roviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989; 245: 616–21.

    Google Scholar 

  16. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51: 701–12.

    Google Scholar 

  17. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952–5.

    Google Scholar 

  18. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52: 93–112.

    Google Scholar 

  19. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996; 124: 1039–50.

    Google Scholar 

  20. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011–7.

    Google Scholar 

  21. Vella S, Galluzzo C, Giannini G, et al. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA hanges, and emergence of HIV straines with reduced phenotypic sensitivity. Antiviral Res 1996; 29:91–3.

    Google Scholar 

  22. Lalezari J, Haubrich R, Burger HU, Beattie D, Donatacci L, Salgo MP, and the NV 14256 Study Team. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase TM, SQV) plus Hivid (zalcitabine, ddC). XI International Conference on AIDS, Vancouver, July 1996, LB.B.6033.

  23. Salgo MP, Beattie D, Bragman K, Donatacci L, Jones M, Montgomery L, the NV 14256 Study Team. Saquinavir (Invirase, SQV) vs. Hivid (zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/ unable to take Retrovir (zidovudine (ZDV). XI International Conference on AIDS, Vancouver, July 1996, Mo.B.410.

  24. Baruch A, Mastrodonato-Delora P, Schnipper E, Salgo M. Efficacy and safety of triple combination therapy with Invirase (saquinavir/SQV/HIV protease inhibitor), Epivir (3TC/lamivudine) and Retrovir (r) (ZDV/zidovudine) in HIV-infected patients. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.172.

  25. Rutschmann OT, Kaiser L, Gabriel V, Fathi M, Perrin L, Hirschel B. Adding saquinavir to d4T in advanced HIV-1 infection. XI International Conference on AIDS, Vancouver, July 1996, Th.B.945.

  26. Cameron W. Ritonavir plus saquinavir combination therapy. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, SS5.6.

  27. Hirschel B, Rutschmann O, Hathi M, Gabriel V, Mendoula A, von Overbeck I, et al. Treatment of advanced HIV infection with ritonavir plus saquinavir. XI International Conference on AIDS, Vancouver, July 1996, LB.B.6030.

  28. Workman C, Downie J, Smith DE, Sutherland D, Michelmore H, Dyer W, et al. Combination therapies in primary HIV infection. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, OP1.1.

  29. Craig JC, Whittaker L, Duncan IB, et al. In vitro resistance to an inhibitor of HIV proteinase (Ro 31-8959) relative to inhibitors of reverse transcriptase (AZT and TIBO). Antiviral Chem Chemother 1993; 4: 335–9.

    Google Scholar 

  30. Dianzani F, Antonelli G, Turriziani O, et al. In vitro selection of human immunodeficiency virus type 1 resistant to Ro 31-8959 proteinase inhibitor. Antiviral Chem Chemother 1993; 4: 329–33.

    Google Scholar 

  31. Jacobsen H, Craig CJ, Duncan IB, et al. Molecular characterization of HIV-variants with reduced sensitivity to Ro 31-8959, a viral proteinase inhibitor. AIDS Res Hum Retroviruses 1994; 10 Suppl 1: S24.

    Google Scholar 

  32. Turriziani O, Antonelli G, Jacobsen H, Mous J, Riva E, Pistello M, et al. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol 1994; 38: 297–8.

    Google Scholar 

  33. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED, et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995; 39: 1704–10.

    Google Scholar 

  34. Eberle J, Bechowsky B, Rose D, Hansen U, von den Helm K, Gurtler L, et al. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses 1995;11: 671–6.

    Google Scholar 

  35. Jacobsen H, Yasargil K, Winslow Dl, Craig JC, Krohn A, Duncan Ib, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206: 527–34.

    Google Scholar 

  36. Roberts NA. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995; 9 Suppl 2: S27–S32.

    Google Scholar 

  37. Merrill Dp, Manion Dj, Chou T-C, Hirsch Ms. Protease inhibitor combination regimens against HIV-1 in vitro. 36 th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, I2.

  38. Partaledis Ja, Yamaguchi K, Tisdale M, Blair Ee, Falcione C, Maschera B, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995; 69: 5228–35.

    Google Scholar 

  39. Condra Jh, Schleif WA, Blahy Om, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569–71.

    Google Scholar 

  40. Race E, Gilbert SM, Tomlinson PW, Whittaker L, Moffat A, Jupp R, et al. Long term treatment with saquinavir (invirase) does not lead to a significant reduction in sensitivity to MK-639. XI International Conference on AIDS, Vancouver, July 1996, Tu.B.2124.

  41. Williams PEO, Sampson AP, Green CP, et al. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers. Br J Clin Pharmacol 1992; 34: 155P–156P.

    Google Scholar 

  42. Muirhead GJ, Shaw T, Williams PEO, et al. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 31-8959, after single and multiple oral doses in healthy volunteers. Br J Clin Pharmacol 1992; 34: 170P–171P.

    Google Scholar 

  43. Shaw TM, Muirhead GJ, Parish N, et al. Tolerability and phar macokinetics of single oral doses of Ro 31-8959, an HIV proteinase inhibitor. Br J Clin Pharmacol 1994; 34: 166P–167P.

    Google Scholar 

  44. Farrar G, Mitchell AM, Hooper H, et al. Prediction of potential drug interactions of saquinavir (Ro 31-8959) from in vitro data. Br J Clin Pharmacol 1994; 38: 162P.

    Google Scholar 

  45. Kodjo A, Dumitrescu L, Crivat M, Trout H, Dohin E, Vittecoq D, et al. Digestive absorption of saquinavir in AIDS patients with severe diarrhea or wasting syndrome. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, P24.

  46. Sahai J, Stewart F, Swick L, Gallicano K, Garber G, Seguin I, et al. Rifabutin (RFB) reduces saquinavir (SAQ) plasma levels in HIV-infected patients. 36 th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, A27.

  47. Norbeck D, Kumar G, Marsh K, Rodrigues D, McDonald E, Molla A, et al. Ritonavir and saquinavir: potential for twodimensional synergy between HIV protease inhibitors. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995, LB7.

  48. Hsu A, Granneman GR, Sun E, Chen P, El-Shourbagy T, Locke C, et al. Assessment of single-and multiple-dose interactions between ritonavir and saquinavir. XI International Conference on AIDS, Vancouver, July 1996, LB.B.6041.

  49. Merry C, Barry M, Mulcahy F, Heavey J, Tjia J, Gibbons S, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in patients with HIV disease. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, OP6.1.

  50. Anonymous. Saquinavir package insert.

  51. Vacca JP, Guare JP, de Solms SJ, Sanders WM, Giuliani EA, Young SD, et al. L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J Med Chem 1991; 34: 1225–8.

    Google Scholar 

  52. Lyle TA, Wiscount CM, Guare JP. Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. J Med Chem 1991; 34: 1228–30.

    Google Scholar 

  53. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, et al. L-735,524: the design of a potent and orally bioav ailable HIV protease inhibitor. J Med Chem 1994; 37: 3443–51.

    Google Scholar 

  54. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994; 90: 4096–4100.

    Google Scholar 

  55. Balani SK, Arison BH, Mathai L, Kauffman LR, Miller RR, Stearns RA, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995; 23: 266–70.

    Google Scholar 

  56. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10: 485–92.

    Google Scholar 

  57. Chodakewitz J, Deutsch P, Leavitt R, Massari F, Hildebrand C, Justice S, et al. Preliminary evaluation of the long term safety and antiviral activity exerted by Crixivan (MK-639), an oral HIV protease inhibitor. V European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, September 1995, abstract 43.

  58. Mellors J. A randomized, double-blind study of the oral HIV protease inhibitor, L-735,524 vs. AZT in p24 antigenemic, HIV-1 infected patients with < 500 CD4 cells. 2nd National Conference on Human Retroviruses, Washington DC, 1995, 183.

  59. Steigbigel R, Berry P, Teppler H, Mellors J, Drusano G, Leavitt R, et al. Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 g/day), 1000 mg q8h (3.0 g/day) and 800 mg q6h (3.2 g/day). XI International Conference on AIDS, Vancouver, July 1996, Mo.B.412.

  60. Mueller BU, Smith S, Sleasman J, Nelson Jr RP, Meyer C, Deutsch P, et al. A phase I/II study of the protease inhibitor indinavir (MK-0639) in children with HIV Infection. XI International Conference on AIDS, Vancouver, July 1996, We.B.554.

  61. Chodakewitz JA, Leavitt R, Massari F, Hildebrand C, Arcuri K, Gilde L, et al. Crixivan: summary of 24-week experience with Crixivan at 2.4 g/d in phase II trials. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1144.

  62. Gulick RM, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). XI International Conference on AIDS, Vancouver, July 1996, Th.B.931.

  63. Massari F, Staszewski S, Berry P, Kahn J, Frank I, Heath-Chiozzi M, et al. A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine naive patients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995, LB6.

  64. Suleiman J, Lewi D, Uip D, Pedro R, Suleiman G, Accetturi C, et al. Antiretroviral activity and safety of indinavir (IDV) alone and in combination with zidovudine (ZDV) in ZDV-naive patients with CD4 cell counts of 50-250 cells/mm 3. XI International Conference on AIDS, Vancouver, July 1996, LB.B.6017.

  65. Berry P, Kahn J, Cooper R, Chung M, Meibohm A, Arcuri K, et al. Antiretroviral activity and safety of indinavir (IDV) alone and in combination with zidovudine (ZDV) in ZDV-naive patients with CD4 cell counts of 50-500 cell/mm 3. XI International Conference on AIDS, Vancouver, July 1996, LB.B.6019.

  66. Leavitt R, Massari F, Nessly M, Meibohm A, Getson A, Chodakewitz J. Antiviral activity of indinavir (IDV) plus zidovudine (ZDV) compared to IDV or ZDV alone in antiretroviral naive patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, I109.

  67. Falloon J, Owen C, Kovacs J, Leavitt R, Metcalf J, Lane HC. MK-639 (Merck HIV protease inhibitor) with interleukin-2 (IL2) in HIV. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995, I86.

  68. Falloon J, Owen C, Metcalf J, Fyfe G, Lane HC. Indinavir and interleukin-2 in HIV: one year follow-up. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, I108.

  69. Anonymous. AIDS/HIV treatment directory. 1996; 8: 42–3.

  70. Condra JH, Holder DJ, Schleif WA, Chodakewitz JA, Massari FE, Blahy OM, et al. Bi-directional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors. XI International Conference on AIDS, Vancouver, July 1996, Th.B.932.

  71. Anonymous. Indinavir package insert.

  72. Squires KE, Saag MS, Teppler H, Pomerantz R, Waldman S, Bjornsson T, et al. Phase I studies of L-735,524, an HIV pro-tease inhibitor: pharmacokinetics, tolerability and short-term antiviral activity. Clin Res 1994; 42: 280A.

    Google Scholar 

  73. Waldman SA, Teppler H, Osborne B, Bjornsson TD, Pomerantz R, Woolf E, et al. Pharmacokinetics of L-735,524, an HIV protease inhibitor. Clin Pharmacol Ther 55:195 (PIII–52).

  74. Anonymous. Data on file MSD.

  75. The Indinavir (MK 639) Pharmacokinetic Study Group, Merck Research Labs. Indinavir (MK 639) drug interaction studies. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.174.

  76. De Wit S, Turner D, Debier M, Desmet M, Mc Crea J, Matthews C, et al. Absence of interaction between indinavir and fluconazole; a pharmacokinetic study in HIV patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, A26.

  77. Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR). Norvir. 16 August 1996, CPMP/527/96.

  78. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528–33.

    Google Scholar 

  79. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534–9.

    Google Scholar 

  80. Hicks CB, Lehman L, Eron, Horton J, Jemsek J, Kelly N, et al. Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.415.

  81. Mueller BU, Zuckerman J, Nelson Jr RP, Sleasman J, Vora S, Saulis R, et al. A phase I/II study of the protease inhibitor ritonavir (ABT-538) in children with HIV infection. XI International Conference on AIDS, Vancouver, July 1996, We.B.551.

  82. Cameron B, Heath-Chiozzi M, Kravick S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Update. XI Conference on AIDS, Vancouver, July 1996, Mo.B.411.

  83. Heath-Chiozzi M, Leonard J, Sun E, Lehman L, Henry D, Kravcik S, et al. Ritonavir clinical benefit correlates with HIV RNA and CD4 cell levels in advanced HIV illness. XI International Conference on AIDS, Vancouver, July 1996, We.B.3127.

  84. Mathez D, Bagnarelli P, De Truchis P, Gorin I, Katlama C, Pialoux G, et al. A triple combination of ritonavir + AZT + ddC as a first line treatment of patients with AIDS: update. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.175.

  85. Notermans DW, de Wolf F, Foudraine NA, Meenhorst PL, Kauffman RH, McDade H, et al. The effects of an antiretroviral triple combination with ritonavir, AZT and 3TC. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, OP8.2.

  86. Danner SA. Immediate versus delayed triple therapy with ritonavir, AZT and 3TC. Abbott Satellite Symposium, 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996.

  87. Markowitz M, Cao Y, Hurley A, O'Donovan R, Heath-Chiozzi M, Leonard J, et al. Triple therapy with AZT, 3TC and ritonavir in 12 subjects newly infected with HIV-1. XI International Conference on AIDS, Vancouver, July 1996, Th.B.933.

  88. Korneyeva M, Molla A, Kempf D, Vasavanonda S, Chernyavskia T, Boucher C, et al. Clinical and virological responses to ritonavir, an inhibitor of HIV protease. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1137.

  89. Hsu A, Granneman R, Rynkiewicz K, Valdes J, Mayer K, Leonard J. Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses. American Association of Pharmaceutical Scientists Ninth Annual Meeting & Exposition, San Diego, November 1994, PPDM 8272.

  90. Bertz R, Shi H, Cavanaugh J, Hsu A. Effect of three vehicles, Advera (r), Ensure (r), and chocolate milk, on the bioavailability of an oral liquid formulation of Norvir (r) (ritonavir). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, A25.

  91. Molla A, Kempf D, Korneyeva M, et al. Characterization of the in vivo resistance pathway and pharmacokinetic properties of ritonavir. Vth International Workshop on HIV Drug Resistance, Whistler, July 1996, Abstract 31.

  92. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM. Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1137.

  93. Ouellet D, Hsu A, Qian J, Cavanaugh J, Leonard J, Granneman GR. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1198.

  94. Cato A, Cavanaugh JH, Shi H, Hsu A, Granneman GR, Leonard J. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1199.

  95. Sun E, Heath-Chiozzi M, Cameron DW, Hsu A, Granneman RG, Maurath CJ, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse effects. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.171.

  96. Hsu A, Granneman GR, Witt G, Cavanaugh JH, Leonard J. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1200.

  97. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM. Effect of ritonavir on the pharmacokinetics of desipramine. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1201.

  98. Cato A, Hsu A, Granneman R, Leonard J, Carlson G, Carothers L, et al. Assessment of the pharmacokinetic inter-action between the HIV-1 protease inhibitor ABT-538 and flu-conazole. 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995.

  99. Anonymous. Ritonavir package insert.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy & Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands

    R.M.W. Hoetelmans, C.H.W. Koks, J.H. Beijnen, P.L. Meenhorst & J.W. Mulder

  2. Department of Clinical Pharmacy, University Hospital Nijmegen, Nijmegen, the Netherlands

    D.M. Burger

Authors
  1. R.M.W. Hoetelmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C.H.W. Koks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P.L. Meenhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J.W. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D.M. Burger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoetelmans, R., Koks, C., Beijnen, J. et al. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 19, 159–175 (1997). https://doi.org/10.1023/A:1008629608556

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008629608556

Search

Navigation